Noxxon promotes Aram Mangasarian to Chief Executive

He has already been at the company for five years as Chief Business Officer

Dr Aram Mangasarian has replaced Iain Buchanan as Chief Executive at German biotechnology company Noxxon Pharma. Buchanan will join the company's supervisory board as a Non-executive Director.

Mangasarian joined Noxxon in May 2010 and since then has led business development as Chief Business Officer, working with Buchanan on the Executive Committee.

Buchanan, who took up the role of CEO in September 2010, steps down from the operational day-to-day business, but will continue to work with the management team before he rejoins the supervisory board.

Mangasarian has more than 15 years of experience in biotechnology and pharmaceutical business development. He began his career at ExonHit Therapeutics (now Diaxonhit), in May 2000, eventually heading the business development function as Vice-President.

He joined Novexel as Vice-President Business Development in October 2005.

Noxxon Pharma is a clinical-stage biopharmaceutical company developing Spiegelmers, a novel class of proprietary nucleic acid-based therapeutic agents built on a backbone of mirror-image nucleotides. Spiegelmers are chemically synthesised L-stereoisomer oligonucleotide aptamers, an immunologically passive alternative to antibodies.

You may also like

Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Subscribe now